Possible metformin-induced hepatotoxicity
Abstract
BACKGROUND: Metformin hydrochloride is widely used for the treatment of type 2 diabetes mellitus (DM-2). To date, only 2 cases of possible metformin-induced hepatotoxicity (acute hepatitis) have been reported worldwide.
OBJECTIVE: The aim of this article was to report a case of serious hepatotoxicity possibly associated with metformin use in an elderly patient with DM-2.
METHODS: After receiving metformin 500 mg/d for 3 weeks, a 73-year-old Japanese woman weighing 33.5 kg with poorly controlled DM-2 presented with fatigue, jaundice, nausea, vomiting, anorexia, and abdominal pain. Laboratory analysis showed severe hepatotoxicity (elevated aspartate and alanine aminotransferases [AST and ALT, respectively], alkaline phosphatase [ALP], and total bilirubin concentrations). The history, clinical findings, laboratory features, and clinical course of this case, as well as the pharmacologic profile of metformin, are presented.
RESULTS: Immediate hospitalization and discontinuation of metformin treatment led to improvements in liver function (decreased AST, ALT, ALP, and total bilirubin concentrations) and resolution of the presented symptoms within 3 weeks. The probability of an adverse drug reaction (ADR), as assessed using the Naranjo ADR probability scale, in this case was 4 (probable).
CONCLUSIONS: In this case of an elderly woman with DM-2 who presented with symptoms of hepatotoxicity after 3 weeks of metformin treatment, metformin appeared to have caused a mixed-type…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.